Navigation Links
Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo

significance. For TST, the 50 mg dose achieved significance (p=0.024) and the 20 and 100 mg doses showed a trend toward significance.

"VEC-162 induces and maintains sleep by modulating the sleep/wake cycle," said Paolo Baroldi, M.D., Ph.D., Chief Medical Officer, Vanda Pharmaceuticals Inc. "The subjective findings suggest the compound's unique mechanism of action provides a noticeable improvement in overall sleep quality."

About Insomnia

Approximately 70 million American adults experience insomnia of all types, characterized by difficulty falling asleep, waking frequently during the night, waking too early and not being able to return to sleep, or waking up not feeling refreshed. Circadian Rhythm Sleep Disorders (CRSD), one type of insomnia, affect millions of Americans in a number of forms. Shift Worker Sleep Disorder is a CRSD affecting the 14% of Americans who are shift workers. Another CRSD type is Delayed Sleep Phase Syndrome, which affects 5-10% of patients in sleep disorder clinics and accounts for 40% of disorders involving sleep-wake schedules.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., headquartered in Rockville, Maryland, is a biopharmaceutical company working to advance the science of personalized medicine to improve the lives of patients with various CNS disorders, including insomnia and schizophrenia. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and has completed its Phase III program. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound in Phase II for the treatment of excessive sleepiness. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com .

N
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:5/22/2013)... GROVE, Minn. , May 22, 2013 ... announced the successful completion of its global ... topiramate), an internally developed program for the ... company,s proprietary formulation technology.  USL255 is specifically ... reduce fluctuations in topiramate blood levels observed ...
(Date:5/22/2013)... , May 22, 2013  Generex Biotechnology Corporation ... demonstrating the superiority of the AE37 breast cancer vaccine ... ( www.antigenexpress.com ). The presentations will be made at ... Oncology (ASCO) to be held in Chicago ... The presentation entitled " Booster inoculations of ...
(Date:5/22/2013)...  Grifols, ein globales Unternehmen der Gesundheitsbranche ... , Spanien, präsentierte die Ergebnisse einer Studie, ... PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des Alpha1-Proteins ... Niveau anhebt, das innerhalb des für gesunde ... eine lebensbedrohliche, genetische Erkrankung, bei der der ...
Breaking Medicine Technology:Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4
(Date:5/22/2013)... that hospitals may be reaping enormous income for ... bloodstream infections contracted in their intensive care units. ... in the American Journal of Medical Quality ... who develops an avoidable central line-associated bloodstream infection ... for than a similar infection-free patient. Moreover, hospitals ...
(Date:5/22/2013)... 22, 2013 Recent tragedies including ... the school shooting in Newtown, Connecticut all resulted ... , Emergency medical practitioners train to respond ... Emergency Medical Services for Children (EMSC) Program specifically ... for the youngest patients. It is estimated 30 ...
(Date:5/22/2013)... 22, 2013 Space Girl Organics ... sponsor for this weekend's I Talk to Strangers Miracle ... am at Cocoa Riverside Park in Cocoa, FL. The event ... Talk to Strangers social movement. , As a sponsor, Space ... to participate in the event. Additionally, they are providing bananas ...
(Date:5/22/2013)... Pamela Isom, President and CEO of ICE ... 2013 Women of Influence Award in recognition for her ... reception took place on Thursday, May 2 at The ... particularly humbling for the 5,000 people ICE Safety Solutions ... to recognize the four to nine lives saved per ...
(Date:5/22/2013)... 2013 Homeopathic Vibes is implementing new store ... to the store during normal hours. On Wednesdays, they will ... to accommodate some of our patients who work shifts that ... or on Saturdays,” says owner and homeopathic consultant, Harminder Singh. ... 6 p.m. Monday through Friday; weekends are by appointment only. ...
Breaking Medicine News(10 mins):Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care 2Health News:Space Girl Organics to Sponsor May 25 Miracle Run/Walk 2Health News:Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award 2Health News:Homeopathic Vibes Now Open Late on Wednesdays 2
... YORK, NY, Sept. 10 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - ... acquires, and develops novel drug targets that disrupt the ... a patent for a potential blockbuster drug target that ... a tailor-made lipid which induces cell death in breast ...
... Immediately after President Obama,s speech to a Joint Session of ... nation,s top political, legislative and communications strategists -- representing a ... and public relations. , , The ... very happy with the speech, but most reactions were short ...
... ... rights to a suite of intellectual property owned by Spherofix AB. , ... Charlotte, NC (PRWEB) September 10, ... acquired exclusive rights to a suite of intellectual property owned by Spherofix AB., , ...
... Netherlands, September 10 The Danish Council,for Strategic Research ... Thursday, September 10. The purpose of their visit is ... and the concrete results,that are being booked by this ... cited TI Pharma as a prime example of public-private,collaboration ...
... Sept. 9 Family Research Council President Tony Perkins made ... a joint session of Congress. , , ... , Tomorrow night in a live webcast at ... address. Perkins will be joined by Senator Jim DeMint (R-SC), ...
... , WASHINGTON, Sept. 9 America,s ... Ignagni, President and CEO: , , "We agree ... plans last year did something industries rarely do: stepped up and ... American people. We proposed health insurance reform to guarantee coverage ...
Cached Medicine News:Health News:GENova files patent for new breast cancer treatment 2Health News:Clarus Research Group Survey: Top Political Strategists React to Obama's Health Care Speech, Rate Effectiveness 2Health News:Clarus Research Group Survey: Top Political Strategists React to Obama's Health Care Speech, Rate Effectiveness 3Health News:Kapstone Medical Acquires Exclusive License to New Orthopedic Technology 2Health News:Dutch Top Institute Pharma Attracts International Interest 2Health News:President Obama's Campaign Style Speech Points to a Health Care Plan on Life Support 2
... range of diagnosis by using the Convex Scanning ... clear image of blood flow by using the ... accessory elevator has been incorporated and the balloon ... for more advanced and accurate techniques. The FG-36UX ...
... ACL 10000 allows you to maximize your ... staff are limited. This fully automated system ... analysis and advanced robotics, to ensure testing ... the ACL 10000 is backed by our ...
The SYNCHRON CX7-S workstation offers a broad menu, advanced data management and more. Targeted to the mid-volume lab, the CX7-S is easy to use, easy to maintain and easy to acquire....
... CX5 Delta takes the automation and ... and adds the benefit of electrolyte ... chemistry system for the low- to ... capabilities and continuous sample loading. The ...
Medicine Products: